Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy

Xiaodan Cao, Haijun Yu, Chao Chen, Jia Wei, Ping Wang

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Objectives: The availability of self-targeting and low immunogenic therapeutic agents is critical to efficient cancer therapy. Therefore, the development of humanized therapeutic antibodies is particularly appealing. Results: A humanized single-chain variable fragment (scFv) antibody that can target human epidermal growth factor receptor-2 (HER2)-overexpressing cancer cells was designed and produced via expression in Pichia pastoris. The expression gave a high yield of 8 mg protein/l (with a purity of 92 %) using shake-flask cultures. Functional studies also revealed that the purified recombinant anti-HER2 scFv exhibited anti-proliferative activity and could bind efficiently to HER2-overexpressing human breast cancer cell line SKBR3. Conclusion: The recombinant scFv offers promising therapeutic and binding efficiencies that are desirable for targeted cancer therapies.

Original languageEnglish (US)
Pages (from-to)1347-1354
Number of pages8
JournalBiotechnology Letters
Volume37
Issue number7
DOIs
StatePublished - Jul 5 2015

Keywords

  • Anti-HER2
  • Breast cancer cell line SKBR3
  • Cancer therapy
  • Heterogeneous expression
  • Humanized single-chain variable fragment
  • Pichia pastoris

Fingerprint Dive into the research topics of 'Expression and characterization of recombinant humanized anti-HER2 single-chain antibody in Pichia pastoris for targeted cancer therapy'. Together they form a unique fingerprint.

Cite this